Bioventus (Bioventus) Change In Receivables : $-5.1 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bioventus Change In Receivables?

Bioventus's change in receivables for the quarter that ended in Mar. 2024 was $-2.0 Mil. It means Bioventus's Accounts Receivable increased by $2.0 Mil from Dec. 2023 to Mar. 2024 .

Bioventus's change in receivables for the fiscal year that ended in Dec. 2023 was $10.1 Mil. It means Bioventus's Accounts Receivable declined by $10.1 Mil from Dec. 2022 to Dec. 2023 .

Bioventus's Accounts Receivable for the quarter that ended in Mar. 2024 was $125.5 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Bioventus's Days Sales Outstanding for the three months ended in Mar. 2024 was 88.49.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Bioventus's liquidation value for the three months ended in Mar. 2024 was $-409.0 Mil.

Bioventus Change In Receivables Historical Data

The historical data trend for Bioventus's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioventus Change In Receivables Chart

Bioventus Annual Data

Trend

Dec13

Dec14

Dec15

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-14.91

-3.94

-20.05

-17.67

10.06

Bioventus Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															13.16	-1.83	7.92	-9.19	-1.96

Bioventus Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.1 Mil.

Bioventus (NAS:BVS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Bioventus's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	125.541	/	129.457	*	91
=	88.49

2. In Ben Graham's calculation of liquidation value, Bioventus's accounts receivable are only considered to be worth 75% of book value:

Bioventus's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	25.173	-	576.806	+	0.75 * 125.541	+	0.5 * 97.005
=	-409.0

Bioventus Change In Receivables Related Terms

Thank you for viewing the detailed overview of Bioventus's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioventus (Bioventus) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bioventus Inc (NAS:BVS) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

4721 Emperor Boulevard, Suite 100, Durham, NC, USA, 27703

Website

https://www.bioventus.com

Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in U.S and International markets.

Executives

Bihl Anthony P Iii	director, officer: Interim CEO	807 SMITH RIDGE ROAD, NEW CANAAN CT 06840
John A. Bartholdson	director, 10 percent owner	C/O STONINGTON PARTNERS, INC., 540 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Juniper Investment Company, Llc	10 percent owner	555 MADISON AVENUE, 24TH FLOOR, NEW YORK NY 10022-3315
Katrina J Church	officer: SVP & Chief Compliance Officer	3290 WEST BAYSHORE ROAD, PALO ALTO CA 94303
Alexis P Michas	10 percent owner	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Juniper Targeted Opportunities, Lp	10 percent owner	555 MADISON AVENUE, 24TH FL, NEW YORK NY 10022
Juniper Targeted Opportunity Fund, L.p.	10 percent owner	555 MADISON AVENUE, 24TH FLOOR, NEW YORK NY 10022
William A Hawkins	director	MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Mark Leonard Singleton	officer: SEE REMARKS	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
Anthony D'adamio	officer: SVP & General Counsel	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Kenneth Michael Reali	director, officer: Chief Executive Officer	5213 ATHERTON BRIDGE ROAD, RALEIGH NC 27613
John Nosenzo	officer: Chief Commercial Officer	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Alessandra Pavesio	officer: SVP & Chief Science Officer	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Gregory O. Anglum	officer: SVP and CFO	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
Michelle Mcmurry-heath	director	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703